Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Tivantinib (Primary) ; Carboplatin; Pemetrexed
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.